cgem-10q_20210930.htm
false Q3 --12-31 0001789972 Yes Yes http://fasb.org/us-gaap/2021-01-31#LicenseMember http://fasb.org/us-gaap/2021-01-31#LicenseMember http://fasb.org/us-gaap/2021-01-31#LicenseMember http://fasb.org/us-gaap/2021-01-31#LicenseMember 0001789972 2021-01-01 2021-09-30 xbrli:shares 0001789972 2021-11-02 iso4217:USD 0001789972 2020-12-31 0001789972 2021-09-30 iso4217:USD xbrli:shares 0001789972 2020-07-01 2020-09-30 0001789972 2021-07-01 2021-09-30 0001789972 2020-01-01 2020-09-30 0001789972 us-gaap:CommonStockMember 2019-12-31 0001789972 us-gaap:NoncontrollingInterestMember 2019-12-31 0001789972 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001789972 us-gaap:RetainedEarningsMember 2019-12-31 0001789972 2019-12-31 0001789972 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001789972 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001789972 2020-01-01 2020-03-31 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001789972 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001789972 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001789972 us-gaap:CommonStockMember 2020-03-31 0001789972 us-gaap:NoncontrollingInterestMember 2020-03-31 0001789972 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001789972 us-gaap:RetainedEarningsMember 2020-03-31 0001789972 2020-03-31 0001789972 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0001789972 2020-04-01 2020-06-30 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001789972 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001789972 us-gaap:CommonStockMember 2020-06-30 0001789972 us-gaap:NoncontrollingInterestMember 2020-06-30 0001789972 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001789972 us-gaap:RetainedEarningsMember 2020-06-30 0001789972 2020-06-30 0001789972 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001789972 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001789972 us-gaap:CommonStockMember 2020-09-30 0001789972 us-gaap:NoncontrollingInterestMember 2020-09-30 0001789972 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001789972 us-gaap:RetainedEarningsMember 2020-09-30 0001789972 2020-09-30 0001789972 2021-01-01 2021-03-31 0001789972 us-gaap:CommonStockMember 2020-12-31 0001789972 us-gaap:NoncontrollingInterestMember 2020-12-31 0001789972 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001789972 us-gaap:RetainedEarningsMember 2020-12-31 0001789972 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001789972 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001789972 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001789972 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001789972 us-gaap:CommonStockMember 2021-03-31 0001789972 us-gaap:NoncontrollingInterestMember 2021-03-31 0001789972 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001789972 us-gaap:RetainedEarningsMember 2021-03-31 0001789972 2021-03-31 0001789972 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001789972 2021-04-01 2021-06-30 0001789972 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001789972 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001789972 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001789972 us-gaap:CommonStockMember 2021-06-30 0001789972 us-gaap:NoncontrollingInterestMember 2021-06-30 0001789972 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001789972 us-gaap:RetainedEarningsMember 2021-06-30 0001789972 2021-06-30 0001789972 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001789972 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001789972 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001789972 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001789972 us-gaap:CommonStockMember 2021-09-30 0001789972 us-gaap:NoncontrollingInterestMember 2021-09-30 0001789972 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001789972 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001789972 us-gaap:RetainedEarningsMember 2021-09-30 cgem:Subsidiary 0001789972 us-gaap:IPOMember 2021-01-01 2021-01-31 0001789972 us-gaap:OverAllotmentOptionMember 2021-01-01 2021-01-31 0001789972 us-gaap:IPOMember 2021-01-31 0001789972 2021-01-01 2021-01-31 xbrli:pure 0001789972 cgem:ShortTermInvestmentMember us-gaap:CorporateNoteSecuritiesMember 2020-12-31 0001789972 cgem:ShortTermInvestmentMember us-gaap:CommercialPaperMember 2020-12-31 0001789972 cgem:ShortTermInvestmentMember us-gaap:AssetBackedSecuritiesMember 2020-12-31 0001789972 us-gaap:CorporateNoteSecuritiesMember cgem:ShortTermInvestmentMember 2021-09-30 0001789972 us-gaap:CommercialPaperMember cgem:ShortTermInvestmentMember 2021-09-30 0001789972 us-gaap:USGovernmentAgenciesDebtSecuritiesMember cgem:ShortTermInvestmentMember 2021-09-30 0001789972 cgem:ShortTermInvestmentMember 2021-09-30 0001789972 us-gaap:CorporateNoteSecuritiesMember cgem:LongTermInvestmentMember 2021-09-30 0001789972 us-gaap:AssetBackedSecuritiesMember cgem:LongTermInvestmentMember 2021-09-30 0001789972 cgem:LongTermInvestmentMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-09-30 0001789972 cgem:LongTermInvestmentMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CashMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateNoteSecuritiesMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CashMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateNoteSecuritiesMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2021-09-30 0001789972 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-09-30 0001789972 us-gaap:SeriesCPreferredStockMember cgem:CullinanOncologyLLCMember 2021-01-01 2021-09-30 0001789972 us-gaap:SeriesBPreferredStockMember cgem:CullinanOncologyLLCMember 2021-01-01 2021-09-30 0001789972 cgem:SeriesA1PreferredUnitsMember cgem:CullinanOncologyLLCMember 2021-01-01 2021-09-30 0001789972 cgem:SeriesSeedPreferredUnitsMember cgem:CullinanOncologyLLCMember 2021-01-01 2021-09-30 0001789972 cgem:NonVotingIncentiveUnitsMember cgem:CullinanOncologyLLCMember 2021-01-01 2021-09-30 0001789972 cgem:CommonUnitsMember cgem:CullinanOncologyLLCMember 2021-01-01 2021-09-30 0001789972 cgem:CullinanOncologyLLCMember 2021-01-01 2021-09-30 0001789972 cgem:SeriesSeedRedeemablePreferredUnitsMember srt:ScenarioPreviouslyReportedMember 2019-12-31 0001789972 cgem:SeriesSeedRedeemablePreferredUnitsMember srt:RestatementAdjustmentMember 2019-12-31 0001789972 cgem:SeriesA1RedeemablePreferredUnitsMember srt:ScenarioPreviouslyReportedMember 2019-12-31 0001789972 cgem:SeriesA1RedeemablePreferredUnitsMember srt:RestatementAdjustmentMember 2019-12-31 0001789972 cgem:SeriesBRedeemablePreferredUnitsMember srt:ScenarioPreviouslyReportedMember 2019-12-31 0001789972 cgem:SeriesBRedeemablePreferredUnitsMember srt:RestatementAdjustmentMember 2019-12-31 0001789972 srt:ScenarioPreviouslyReportedMember 2019-12-31 0001789972 srt:RestatementAdjustmentMember 2019-12-31 0001789972 cgem:SeriesSeedRedeemablePreferredUnitsMember srt:ScenarioPreviouslyReportedMember 2020-09-30 0001789972 cgem:SeriesSeedRedeemablePreferredUnitsMember srt:RestatementAdjustmentMember 2020-09-30 0001789972 cgem:SeriesA1RedeemablePreferredUnitsMember srt:ScenarioPreviouslyReportedMember 2020-09-30 0001789972 cgem:SeriesA1RedeemablePreferredUnitsMember srt:RestatementAdjustmentMember 2020-09-30 0001789972 cgem:SeriesBRedeemablePreferredUnitsMember srt:ScenarioPreviouslyReportedMember 2020-09-30 0001789972 cgem:SeriesBRedeemablePreferredUnitsMember srt:RestatementAdjustmentMember 2020-09-30 0001789972 srt:ScenarioPreviouslyReportedMember 2020-09-30 0001789972 srt:RestatementAdjustmentMember 2020-09-30 0001789972 cgem:SeriesSeedRedeemablePreferredUnitsMember srt:ScenarioPreviouslyReportedMember 2020-12-31 0001789972 cgem:SeriesSeedRedeemablePreferredUnitsMember srt:RestatementAdjustmentMember 2020-12-31 0001789972 cgem:SeriesA1RedeemablePreferredUnitsMember srt:ScenarioPreviouslyReportedMember 2020-12-31 0001789972 cgem:SeriesA1RedeemablePreferredUnitsMember srt:RestatementAdjustmentMember 2020-12-31 0001789972 cgem:SeriesBRedeemablePreferredUnitsMember srt:ScenarioPreviouslyReportedMember 2020-12-31 0001789972 cgem:SeriesBRedeemablePreferredUnitsMember srt:RestatementAdjustmentMember 2020-12-31 0001789972 cgem:SeriesCRedeemablePreferredUnitsMember srt:ScenarioPreviouslyReportedMember 2020-12-31 0001789972 cgem:SeriesCRedeemablePreferredUnitsMember srt:RestatementAdjustmentMember 2020-12-31 0001789972 srt:ScenarioPreviouslyReportedMember 2020-12-31 0001789972 srt:RestatementAdjustmentMember 2020-12-31 0001789972 us-gaap:CollaborativeArrangementMember cgem:CullinanOncologyAdimabMember 2021-07-01 2021-09-30 0001789972 us-gaap:CollaborativeArrangementMember cgem:CullinanOncologyAdimabMember 2020-01-01 2020-09-30 0001789972 us-gaap:CollaborativeArrangementMember cgem:CullinanOncologyAdimabMember 2021-01-01 2021-09-30 0001789972 us-gaap:CollaborativeArrangementMember cgem:AmberMITMember 2020-01-01 2020-09-30 0001789972 us-gaap:CollaborativeArrangementMember cgem:AmberMITMember 2021-01-01 2021-09-30 0001789972 us-gaap:CollaborativeArrangementMember cgem:ApolloWistarMember 2020-01-01 2020-09-30 0001789972 us-gaap:CollaborativeArrangementMember cgem:FlorentineTubingenMember 2020-07-01 2020-09-30 0001789972 us-gaap:CollaborativeArrangementMember cgem:FlorentineTubingenMember 2020-01-01 2020-09-30 0001789972 us-gaap:CollaborativeArrangementMember cgem:PearlTaihoPharmaMember 2020-07-01 2020-09-30 0001789972 us-gaap:CollaborativeArrangementMember cgem:PearlTaihoPharmaMember 2020-01-01 2020-09-30 0001789972 us-gaap:CollaborativeArrangementMember cgem:PearlTaihoPharmaMember 2021-01-01 2021-09-30 0001789972 us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0001789972 us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0001789972 us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0001789972 us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0001789972 cgem:PearlZaiLabLicenseAgreementMember 2021-01-01 2021-01-31 0001789972 cgem:PearlZaiLabLicenseAgreementMember srt:MaximumMember 2020-12-30 2020-12-31 0001789972 cgem:PearlTaihoPharmaMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-01-31 0001789972 cgem:SeriesASeniorPreferredStockPurchaseAgreementMember cgem:SeriesASeniorPreferredStockMember cgem:PDITherapeuticsIncMember 2020-05-28 2020-05-28 0001789972 cgem:SeriesASeniorPreferredStockPurchaseAgreementMember cgem:SeriesASeniorPreferredStockMember cgem:PDITherapeuticsIncMember cgem:CertainExistingPDITherapeuticsShareholdersMember 2020-05-28 2020-05-28 0001789972 cgem:SeriesASeniorPreferredStockPurchaseAgreementMember srt:MaximumMember 2021-01-01 2021-09-30 cgem:Milestone 0001789972 cgem:SeriesASeniorPreferredStockPurchaseAgreementMember 2021-01-01 2021-09-30 0001789972 cgem:PDITherapeuticsIncMember 2020-05-28 0001789972 cgem:SeriesAJuniorPreferredStockMember cgem:PDITherapeuticsIncMember 2020-05-28 0001789972 cgem:SeriesA1JuniorPreferredStockMember cgem:PDITherapeuticsIncMember 2020-05-28 0001789972 cgem:SeriesA2JuniorPreferredStockMember cgem:PDITherapeuticsIncMember 2020-05-28 0001789972 cgem:SeriesASeniorPreferredStockMember cgem:PDITherapeuticsIncMember 2020-05-28 0001789972 cgem:CullinanMICACorpMember 2020-05-31 0001789972 cgem:SeriesAJuniorPreferredStockMember cgem:CullinanMICACorpMember 2020-05-31 0001789972 cgem:SeriesAA1AndA2JuniorPreferredStockMember cgem:CullinanMICACorpMember 2020-05-31 0001789972 cgem:SeriesAJuniorPreferredStockMember cgem:CullinanOncologyLLCMember 2020-05-31 0001789972 cgem:MICAEquityPlanMember 2020-05-31 0001789972 cgem:MICAEquityPlanMember cgem:MICAsDirectorsAndOfficersAsWellAsFormerEmployeesOfPDITherapeuticsMember 2020-05-31 0001789972 cgem:CullinanMICACorpMember cgem:FullyDilutedSharesMember 2021-09-30 0001789972 cgem:CullinanMICACorpMember cgem:SeriesASeniorPreferredStockMember 2021-09-30 0001789972 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001789972 cgem:SeriesASeniorPreferredStockMember cgem:MICABoardAuthorizedFirstAdditionalClosingMember 2021-06-01 2021-06-30 0001789972 cgem:SeriesASeniorPreferredStockMember cgem:CertainExistingShareholdersMember cgem:MICABoardAuthorizedFirstAdditionalClosingMember 2021-06-01 2021-06-30 0001789972 us-gaap:SeriesAPreferredStockMember cgem:CullinanAmberCorpMember 2020-04-30 0001789972 us-gaap:SeriesAPreferredStockMember cgem:CullinanAmberCorpMember 2020-04-01 2020-04-30 0001789972 us-gaap:SeriesAPreferredStockMember srt:MaximumMember cgem:CullinanAmberCorpMember 2020-04-01 2020-04-30 0001789972 cgem:LicenseAgreementBetweenAmberAndMassachusettsInstituteOfTechnologyMember 2020-04-30 0001789972 cgem:LicenseAgreementBetweenAmberAndMassachusettsInstituteOfTechnologyMember us-gaap:CommonStockMember 2020-04-01 2020-04-30 0001789972 us-gaap:SeriesAPreferredStockMember 2021-06-30 0001789972 us-gaap:SeriesAPreferredStockMember 2021-06-01 2021-06-30 0001789972 cgem:LicenseAgreementBetweenAmberAndMassachusettsInstituteOfTechnologyMember 2021-06-30 0001789972 cgem:LicenseAgreementBetweenAmberAndMassachusettsInstituteOfTechnologyMember us-gaap:CommonStockMember 2021-06-01 2021-06-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanAmberCorpMember 2020-07-01 2020-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanAmberCorpMember 2020-01-01 2020-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanAmberCorpMember 2021-07-01 2021-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember srt:MaximumMember cgem:CullinanAmberCorpMember 2021-01-01 2021-09-30 0001789972 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001789972 us-gaap:SeriesAPreferredStockMember 2018-12-01 2018-12-31 0001789972 us-gaap:SeriesAPreferredStockMember srt:MaximumMember 2018-12-31 0001789972 cgem:CullinanApolloCorpMember 2020-07-01 2020-09-30 0001789972 cgem:CullinanApolloCorpMember 2020-01-01 2020-09-30 0001789972 cgem:CullinanApolloCorpMember 2021-07-01 2021-09-30 0001789972 cgem:CullinanApolloCorpMember 2021-01-01 2021-09-30 0001789972 cgem:CullinanFlorentineCorpMember us-gaap:SeriesAPreferredStockMember 2020-08-01 2020-08-31 0001789972 cgem:CullinanFlorentineCorpMember us-gaap:SeriesAPreferredStockMember srt:MaximumMember 2020-08-01 2020-08-31 0001789972 cgem:CullinanFlorentineCorpMember us-gaap:SeriesAPreferredStockMember 2020-08-31 0001789972 cgem:CullinanFlorentineCorpMember cgem:TubingenLicenseAgreementMember 2020-08-31 0001789972 cgem:CullinanFlorentineCorpMember cgem:TubingenLicenseAgreementMember us-gaap:CommonStockMember 2020-08-01 2020-08-31 0001789972 us-gaap:SeriesAPreferredStockMember 2020-12-01 2020-12-31 0001789972 us-gaap:CommonStockMember cgem:TubingenLicenseAgreementMember 2020-12-01 2020-12-31 0001789972 cgem:DFKZAndUFEAntiDilutionSharesMember us-gaap:CommonStockMember cgem:TubingenLicenseAgreementMember 2020-12-01 2020-12-31 0001789972 us-gaap:SeriesBPreferredStockMember 2021-07-01 2021-07-31 0001789972 cgem:DFKZAndUFEAntiDilutionSharesMember 2021-07-01 2021-07-31 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanFlorentineCorpMember 2020-07-01 2020-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanFlorentineCorpMember 2020-01-01 2020-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanFlorentineCorpMember 2021-07-01 2021-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanFlorentineCorpMember 2021-01-01 2021-09-30 0001789972 cgem:SeriesASeniorPreferredStockMember 2020-05-31 0001789972 cgem:SeriesASeniorPreferredStockMember 2020-05-01 2020-05-31 0001789972 cgem:CullinanMICACorpMember 2020-05-28 2020-05-28 0001789972 cgem:CullinanMICACorpMember cgem:SeriesASeniorPreferredStockMember 2020-05-28 2020-05-28 0001789972 cgem:CullinanMICACorpMember cgem:JuniorPreferredAndCommonStockholdersMember us-gaap:NoncontrollingInterestMember 2020-05-28 2020-05-28 0001789972 cgem:CullinanMICACorpMember 2020-12-31 0001789972 cgem:CullinanMICACorpMember 2020-12-01 2020-12-31 0001789972 cgem:CullinanMICACorpMember 2021-06-01 2021-06-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanMICACorpMember srt:MaximumMember 2020-07-01 2020-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanMICACorpMember 2020-01-01 2020-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanMICACorpMember 2021-07-01 2021-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanMICACorpMember 2021-01-01 2021-09-30 0001789972 us-gaap:SeriesAPreferredStockMember cgem:TaihoVenturesLLCMember srt:MaximumMember 2019-02-28 0001789972 us-gaap:SeriesAPreferredStockMember cgem:TaihoVenturesLLCMember 2019-02-28 0001789972 us-gaap:SeriesAPreferredStockMember cgem:TaihoVenturesLLCMember 2019-02-01 2019-02-28 0001789972 us-gaap:SeriesAPreferredStockMember cgem:TaihoLicenseAgreementMember 2019-02-28 0001789972 us-gaap:SeriesAPreferredStockMember cgem:TaihoLicenseAgreementMember 2019-02-01 2019-02-28 0001789972 us-gaap:SeriesAPreferredStockMember 2020-08-31 0001789972 us-gaap:SeriesAPreferredStockMember 2020-08-01 2020-08-31 0001789972 us-gaap:SeriesAPreferredStockMember cgem:TaihoLicenseAgreementMember 2020-08-31 0001789972 us-gaap:SeriesAPreferredStockMember cgem:TaihoLicenseAgreementMember 2020-08-01 2020-08-31 0001789972 us-gaap:CommonStockMember cgem:SubscriptionAgreementBetweenCompanyAndPearlMember 2020-11-01 2020-11-30 0001789972 us-gaap:CommonStockMember cgem:SubscriptionAgreementBetweenCompanyAndPearlMember 2020-11-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanPearlCorpMember 2020-07-01 2020-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanPearlCorpMember 2020-01-01 2020-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanPearlCorpMember 2021-07-01 2021-09-30 0001789972 cgem:HypotheticalLiquidationAtBookValueMember cgem:CullinanPearlCorpMember 2021-01-01 2021-09-30 0001789972 cgem:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2021-09-30 0001789972 cgem:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2021-01-01 2021-09-30 0001789972 cgem:TwoThousandTwentyOneStockOptionAndIncentivePlanMember cgem:ExecutiveOfficersEmployeesAndAffiliatesMember 2021-09-30 0001789972 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001789972 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001789972 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001789972 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001789972 cgem:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2021-09-30 0001789972 cgem:TwoThousandTwentyOneEmployeeStockPurchasePlanMember srt:MaximumMember 2021-07-01 2021-09-30 0001789972 cgem:TwoThousandTwentyOneEmployeeStockPurchasePlanMember srt:MaximumMember 2021-01-01 2021-09-30 0001789972 cgem:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2021-06-30 0001789972 cgem:GlobewaysHoldingsLimitedMember cgem:TwoThousandTwentyConsultingAgreementMember 2021-01-01 2021-09-30 0001789972 cgem:GlobewaysHoldingsLimitedMember cgem:TwoThousandTwentyConsultingAgreementMember 2020-04-01 2020-04-30 0001789972 cgem:GlobewaysHoldingsLimitedMember cgem:TwoThousandTwentyConsultingAgreementMember srt:MaximumMember 2021-01-01 2021-09-30 0001789972 cgem:GlobewaysHoldingsLimitedMember cgem:TwoThousandTwentyConsultingAgreementMember srt:MaximumMember 2020-01-01 2020-09-30 0001789972 cgem:GlobewaysHoldingsLimitedMember cgem:TwoThousandTwentyConsultingAgreementMember srt:MaximumMember 2021-07-01 2021-09-30 0001789972 cgem:GlobewaysHoldingsLimitedMember cgem:TwoThousandTwentyConsultingAgreementMember srt:MaximumMember 2020-07-01 2020-09-30 0001789972 cgem:MPMOncologyCharitableFoundationIncMember 2021-01-01 2021-09-30 0001789972 cgem:UBSOptimusFoundationMember 2021-01-01 2021-09-30 0001789972 2020-01-01 2020-12-31 utr:sqft 0001789972 country:MA 2017-12-01 2017-12-31 0001789972 2017-12-01 2017-12-31 0001789972 cgem:FourZeroOneKPlanMember srt:MaximumMember 2020-07-01 2020-09-30 0001789972 cgem:FourZeroOneKPlanMember srt:MaximumMember 2021-07-01 2021-09-30 0001789972 cgem:FourZeroOneKPlanMember srt:MaximumMember 2020-01-01 2020-09-30 0001789972 cgem:FourZeroOneKPlanMember srt:MaximumMember 2021-01-01 2021-09-30 0001789972 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001789972 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001789972 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001789972 cgem:EstimatedSharesIssuableUnderESPPMember 2021-01-01 2021-09-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO                     

Commission File Number: 001-39856

 

CULLINAN ONCOLOGY, INC.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

81-3879991

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

 

One Main Street
Suite 520
Cambridge, MA

02142

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617410-4650

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

CGEM

 

The Nasdaq Global Select Market

 

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES NO 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  YES  NO 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES  NO 

The number of shares of the Registrant’s common stock outstanding as of November 2, 2021 was 43,684,540.

 

 

 

 


 

 

Table of Contents

 

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

 

Item 1.

Financial Statements (unaudited)

 

 

 

Consolidated Balance Sheets

 

3

 

Consolidated Statements of Operations and Comprehensive Loss

 

4

 

Consolidated Statements of Stockholders’ Equity

 

5

 

Consolidated Statements of Cash Flows

 

7

 

Notes to the Consolidated Financial Statements

 

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

24

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

38

Item 4.

Controls and Procedures

 

38

 

 

 

 

PART II.

OTHER INFORMATION

 

 

Item 1.

Legal Proceedings

 

39

Item 1A.

Risk Factors

 

39

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

96

Item 3.

Defaults Upon Senior Securities

 

96

Item 4.

Mine Safety Disclosures

 

96

Item 5.

Other Information

 

96

Item 6.

Exhibits

 

96

 

Signatures

 

98

 

 

 

 

i


 

 

Summary of the Material and Other Risks Associated with Our Business

Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, are summarized in “Risk Factors” and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission, before making an investment decision regarding our common stock.

 

We are early in our development efforts and are substantially dependent on our lead targeted oncology product candidate, CLN-081, and our most advanced product candidates, CLN-049 and CLN-619. If we are unable to advance CLN-081, CLN-049, CLN-619 or any of our other product candidates through clinical development, or to obtain regulatory approval and ultimately commercialize CLN-081, CLN-049 or CLN-619, or any of our other product candidates, either by ourselves or with or by third parties, or if we experience significant delays in doing so, our business will be materially harmed.

 

Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates, and ultimately delay or prevent regulatory approval.

 

Interim, “topline” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data.

 

Our product candidates may cause undesirable side effects or have other properties that delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.

 

Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.

 

We have incurred significant losses since inception and we expect to incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future.

 

We will require substantial additional funding to develop and commercialize our product candidates and identify and invest in new product candidates. If we are unable to raise capital when needed, we would be compelled to delay, reduce or eliminate our product development programs or other operations.

 

We may not be successful in our efforts to use our differentiated hub-and-spoke business model to build a pipeline of product candidates with commercial value.

 

Our subsidiaries are party to certain agreements that provide our licensors, collaborators or other shareholders in our subsidiaries with rights that could delay or impact the potential sale of our subsidiaries or could impact the ability of our subsidiaries to sell assets or enter into strategic alliances, collaborations, or licensing arrangements with other third parties.

 

Our ability to realize value from our subsidiaries may be impacted if we reduce our ownership to a minority interest or otherwise cede control to other investors through contractual agreements or otherwise.

 

A single or limited number of subsidiaries may comprise a large proportion of our value.

 

Our reliance on a central team consisting of a limited number of employees who provide various administrative, research and development and other services across our organization presents operational challenges that may adversely affect our business.

 

We face substantial competition which may result in others discovering, developing or commercializing products before or more successfully than we do.

 

If we are unable to obtain and maintain patent and other intellectual property protection for our current product candidates and technology, or any other product candidates or technology we may develop, or if the scope of intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize CLN-081, CLN-049, CLN-619, or any other product candidates or technology may be adversely affected.

 

We currently rely and expect to continue to rely on the outsourcing of the majority of our development functions to third parties to conduct our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.

 

ii


 

 

The manufacture of drug products, and particularly biologics, is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our current product candidates or any future product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.

 

The novel coronavirus, COVID-19, has and may continue to adversely impact our business, including our preclinical studies and clinical trials and our ability to source drug supply.

 

We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.

 

 

 

 

iii


 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements include, among other things, statements about:

 

the success, cost and timing of our clinical development of our product candidates, including CLN-081, CLN-049 and CLN-619;

 

the initiation, timing, progress, results and cost of our research and development programs and our current and future preclinical and clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;

 

our ability to initiate, recruit and enroll patients in and conduct our clinical trials at the pace that we project;

 

our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations or warnings in the label of any of our product candidates, if approved;

 

our ability to compete with companies currently marketing or engaged in the development of treatments that our product candidates are designed to target;

 

our reliance on third parties to conduct our clinical trials and to manufacture drug substance for use in our clinical trials;

 

the size and growth potential of the markets for oncology, immuno-oncologic diseases and any of our current product candidates or other product candidates we may identify and pursue, and our ability to serve those markets;

 

our ability to identify and advance through clinical development any additional product candidates;

 

the commercialization of our current product candidates and any other product candidates we may identify and pursue, if approved, including our ability to successfully build a specialty sales force and commercial infrastructure to market our current product candidates and any other product candidates we may identify and pursue;

 

the expected benefits of our hub-and-spoke business model, including our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop product candidates;

 

our ability to retain and recruit key personnel;

 

our ability to obtain and maintain adequate intellectual property rights;

 

our expectations regarding government and third-party payor coverage and reimbursement;

 

our estimates of our expenses, ongoing losses, capital requirements and our needs for or ability to obtain additional financing;

 

the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise;

 

our financial performance;

 

developments and projections relating to our competitors or our industry;

 

the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials; and

 

other risks and uncertainties, including those listed under the section titled “Risk Factors.”

 

1


 

 

You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. No forward-looking statement is a guarantee of future performance.

You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed or incorporated by reference as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research, as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Quarterly Report on Form 10-Q, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q.

 

2


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

CULLINAN ONCOLOGY, INC.

Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

 

 

 

December 31,

2020 (1)

 

 

September 30,

2021

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

168,198

 

 

$

88,105

 

Short-term investments

 

 

42,008

 

 

 

232,939

 

Prepaid expenses and other current assets

 

 

2,072

 

 

 

7,794

 

Total current assets

 

 

212,278

 

 

 

328,838

 

Property and equipment, net

 

 

130

 

 

 

89

 

Other assets

 

 

2,300

 

 

 

147

 

Long-term investments

 

 

 

 

 

124,330

 

Total assets

 

$

214,708

 

 

$

453,404

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

9,679

 

 

$

2,024

 

Accrued expenses and other current liabilities

 

 

4,641

 

 

 

5,839

 

Total current liabilities

 

 

14,320

 

 

 

7,863

 

Long-term liabilities:

 

 

 

 

 

 

 

 

Deferred rent

 

 

74

 

 

 

67

 

Total liabilities

 

 

14,394

 

 

 

7,930

 

Commitments and contingencies (Note 11)

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock, $0.0001 par value, 34,900,878 and 150,000,000 shares authorized as of December 31, 2020 and September 30, 2021, respectively; 29,831,125 and 43,660,909 shares issued and outstanding as of December 31, 2020 and September 30, 2021, respectively.

 

 

3

 

 

 

4

 

Additional paid-in capital

 

 

292,348

 

 

 

569,835

 

Accumulated other comprehensive loss

 

 

(2

)

 

 

(58

)

Accumulated deficit

 

 

(93,339

)

 

 

(126,395

)

Total Cullinan stockholders' equity

 

 

199,010

 

 

 

443,386

 

Noncontrolling interests

 

 

1,304

 

 

 

2,088

 

Total stockholders' equity

 

 

200,314

 

 

 

445,474

 

Total liabilities and stockholders' equity

 

$

214,708

 

 

$

453,404

 

 

See accompanying notes to the unaudited consolidated financial statements.

 

(1) The consolidated balance sheet as of December 31, 2020 is derived from the audited consolidated financial statements as of that date and was retroactively adjusted, including shares and per share amounts, as a result of the Reorganization and Reverse Stock Split. See Note 3 to the unaudited consolidated financial statements for additional details.

 

 

 

 

 

3


 

 

CULLINAN ONCOLOGY, INC.

Consolidated Statements of Operations and Comprehensive LOSS

(unaudited)

(in thousands, except share and per share amounts)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2020

 

 

2021

 

 

2020 (1)

 

 

2021

 

License revenue

 

$

 

 

$

 

 

$

 

 

$

18,943

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

9,913

 

 

 

12,680

 

 

 

26,582

 

 

 

36,873

 

General and administrative

 

 

1,586

 

 

 

5,695

 

 

 

4,580

 

 

 

15,677

 

Total operating expenses

 

 

11,499

 

 

 

18,375

 

 

 

31,162

 

 

 

52,550

 

Loss from operations

 

 

(11,499

)

 

 

(18,375

)

 

 

(31,162

)

 

 

(33,607

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

185

 

 

118

 

 

809

 

 

340

 

Other income (expense), net

 

 

 

 

 

(2

)

 

 

1

 

 

 

(12

)

Net loss

 

 

(11,314

)

 

 

(18,259

)

 

 

(30,352

)

 

 

(33,279

)

Net loss attributable to noncontrolling interest

 

 

(1,456

)

 

 

(909

)

 

 

(6,899

)

 

 

(223

)

Net loss attributable to common stockholders of Cullinan

 

$

(9,858

)

 

$

(17,350

)

 

$

(23,453

)

 

$

(33,056

)

Net loss per share, basic and diluted

 

$

(0.50

)

 

$

(0.40

)

 

$

(1.21

)

 

$

(0.76

)

Total weighted-average shares used in computing net loss per share, basic and diluted

 

 

19,721,992

 

 

 

43,438,861

 

 

 

19,453,479

 

 

 

43,254,230

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(11,314

)

 

$

(18,259

)

 

$

(30,352

)

 

$

(33,279

)

Unrealized gain/(loss) on investments

 

 

(144

)

 

 

57

 

 

63

 

 

 

(56

)

Comprehensive loss

 

 

(11,458

)

 

 

(18,202

)

 

 

(30,289

)

 

 

(33,335

)

Comprehensive loss attributable to noncontrolling interest

 

 

(1,456

)

 

 

(909

)

 

 

(6,899

)

 

 

(223

)

Comprehensive loss attributable to Cullinan

 

$

(10,002

)

 

$

(17,293

)

 

$

(23,390

)

 

$

(33,112

)

 

See accompanying notes to the unaudited consolidated financial statements.

 

(1) The shares and per share amounts for the nine months ended September 30, 2020 were derived from the unaudited consolidated financial statements as of that date and were retroactively adjusted as a result of the Reorganization and Reverse Stock Split. See Note 3 to the unaudited consolidated financial statements for additional details.

 

 

4


 

 

 

 

CULLINAN ONCOLOGY, INC.

Consolidated Statements of STOCKHOLDERS’ EQUITY

(unaudited)

(in thousands, except share amounts)

 

 

 

Common Stock

 

 

Noncontrolling

Interest in

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Subsidiaries

 

 

Capital

 

 

(Loss)/Income

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2019 (1)

 

 

18,738,734

 

 

$

2

 

 

$

864

 

 

$

138,543

 

 

$

(4

)

 

$

(41,540

)

 

$

97,865

 

Issuance of common stock equivalents (1)

net of issuance costs of $213

 

 

1,297,700

 

 

 

 

 

 

 

 

 

14,037

 

 

 

 

 

 

 

 

 

14,037

 

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

30

 

 

 

 

 

 

30

 

Net loss

 

 

 

 

 

 

 

 

(190

)

 

 

 

 

 

 

 

 

(4,973

)

 

 

(5,163

)

Balances at March 31, 2020

 

 

20,036,434

 

 

 

2

 

 

 

674

 

 

 

152,580

 

 

 

26

 

 

 

(46,513

)

 

 

106,769

 

Issuance of subsidiary common stock

 

 

 

 

 

 

 

 

175

 

 

 

 

 

 

 

 

 

 

 

 

175

 

Noncontrolling interest acquired in MICA

 

 

 

 

 

 

 

 

5,673

 

 

 

 

 

 

 

 

 

 

 

 

5,673

 

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

177

 

 

 

 

 

 

177

 

Net loss

 

 

 

 

 

 

 

 

(5,253

)

 

 

 

 

 

 

 

 

(8,622

)

 

 

(13,875

)

Balances at June 30, 2020

 

 

20,036,434

 

 

 

2

 

 

 

1,269

 

 

 

152,580

 

 

 

203

 

 

 

(55,135

)

 

 

98,919

 

Issuance of subsidiary common stock

 

 

 

 

 

 

 

 

844

 

 

 

 

 

 

 

 

 

 

 

 

844

 

Issuance of subsidiary preferred stock

 

 

 

 

 

 

 

 

1,206

 

 

 

 

 

 

 

 

 

 

 

 

1,206

 

Unrealized (loss) on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(144

)

 

 

 

 

 

(144

)

Net loss

 

 

 

 

 

 

 

 

(1,456

)

 

 

 

 

 

 

 

 

(9,858

)

 

 

(11,314

)

Balances at September 30, 2020

 

 

20,036,434

 

 

$

2

 

 

$

1,863

 

 

$

152,580

 

 

$

59

 

 

$

(64,993

)

 

$

89,511

 

 

See accompanying notes to the unaudited consolidated financial statements.

 

(1) The consolidated balance sheet as of December 31, 2019 is derived from the audited consolidated financial statements as of such date and was retroactively adjusted, including shares and per share amounts, as a result of the Reorganization and Reverse Stock Split. Changes in stockholders’ equity for the three months ended March 31, 2020, June 30, 2020 and September 30, 2020 were also retroactively adjusted, including shares and per share amounts, as a result of the Reorganization and Reverse Stock Split. See Note 3 to the unaudited consolidated financial statements for additional details.

 

5


 

CULLINAN ONCOLOGY, INC.

Consolidated Statements of STOCKHOLDERS’ EQUITY

(unaudited)

(in thousands, except share amounts)

 

 

 

Common Stock

 

 

Noncontrolling

Interest in

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Subsidiaries

 

 

Capital

 

 

(Loss)

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2020 (1)

 

 

29,831,125

 

 

$

3

 

 

$

1,304

 

 

$

292,348

 

 

$

(2

)

 

$

(93,339

)

 

$

200,314

 

Initial public offering

   net of issuance costs of $22,870

 

 

13,685,000

 

 

 

1

 

 

 

 

 

 

264,515

 

 

 

 

 

 

 

 

 

264,516

 

Equity-based compensation

 

 

 

 

 

 

 

 

5

 

 

 

3,503

 

 

 

 

 

 

 

 

 

3,508

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(58

)

 

 

 

 

 

(58

)

Net income/(loss)

 

 

 

 

 

 

 

 

1,489

 

 

 

 

 

 

 

 

 

(70

)

 

 

1,419

 

Balances at March 31, 2021

 

 

43,516,125

 

 

 

4

 

 

 

2,798

 

 

 

560,366

 

 

 

(60

)

 

 

(93,409

)

 

 

469,699

 

Issuance of subsidiary common stock

 

 

 

 

 

 

 

 

67

 

 

 

 

 

 

 

 

 

 

 

 

67

 

Issuance of subsidiary preferred stock

 

 

 

 

 

 

 

 

923

 

 

 

 

 

 

 

 

 

 

 

 

923

 

Issuance of common stock under employee stock purchase plan

 

 

10,099

 

 

 

 

 

 

 

 

 

180

 

 

 

 

 

 

 

 

 

180

 

Equity-based compensation

 

 

 

 

 

 

 

 

6

 

 

 

4,159

 

 

 

 

 

 

 

 

 

4,165

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(55

)

 

 

 

 

 

(55

)

Net loss

 

 

 

 

 

 

 

 

(803

)

 

 

 

 

 

 

 

 

(15,636

)

 

 

(16,439

)

Balances at June 30, 2021

 

 

43,526,224

 

 

 

4

 

 

 

2,991

 

 

 

564,705

 

 

 

(115

)

 

 

(109,045

)

 

 

458,540

 

Equity-based compensation

 

 

 

 

 

 

 

 

6

 

 

 

4,551

 

 

 

 

 

 

 

 

 

4,557

 

Stock option exercises

 

 

134,685

 

 

 

 

 

 

 

 

 

579

 

 

 

 

 

 

 

 

 

579

 

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

57